Zentalis begins Phase 3 trial dosing for azenosertib in platinum-resistant ovarian cancer patients.

Zentalis Pharmaceuticals has dosed the first patient in the Phase 3 ASPENOVA trial, testing azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer. This trial compares azenosertib to standard chemotherapy and aims to confirm benefits seen in earlier Phase 2 studies, supporting full FDA approval. The ASPENOVA study enrolls about 420 patients globally and focuses on progression-free survival as the primary endpoint. Results from the ongoing Phase 2 DENALI trial, expected by the end of 2026, may lead to accelerated approval, while ASPENOVA will provide confirmatory data for full approval.